Semaglutide
aka Semaglutide (GLP-1 agonist)
Mechanism
Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. It mimics the incretin hormone GLP-1 to regulate appetite and glucose metabolism.
Identification
| CAS number | 910463-68-2 |
|---|---|
| Molecular formula | C187H291N45O59 |
| Typical dose | 0.25–2.4 mg (250–2400 mcg) subcutaneous once weekly; typically titrated from 0.25 mg/week, increasing every 4 weeks |
| Half-life | ~7 days |
Vendors selling Semaglutide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Partners | 50 mg | $335.00 | — | 99 |
| Orbitrex Peptides | 10 mg | $69.99 | — | 95 |
| Orbitrex Peptides | 20 mg | $119.99 | — | 95 |
| Profound Aminos | 5 mg | $79.00 | — | 95 |
| Prime Peptides | 5 mg | $80.00 | — | 95 |
| Prime Peptides | 10 mg | $80.00 | — | 95 |
| Prime Peptides | 15 mg | $80.00 | — | 95 |
| Skye Peptides | 6 mg | $60.00 | — | 90 |
| Qihang Peptide | — | — | — | 87 |
| Peptidegurus | 3 mg | — | — | 84 |
| Peptidegurus | 4 mg | — | — | 84 |
| Peptidegurus | 5 mg | — | — | 84 |
| Peptidegurus | 6 mg | — | — | 84 |
| Peptidegurus | 10 mg | — | — | 84 |
| Reta Peptide | — | — | — | 83 |
| Reta Peptide | — | — | — | 83 |
| Cocer Peptides | 5 mg | $80.00 | — | 82 |
| Blank Peptides | 10 mg | $105.00 | — | 81 |
| Crystal Peptides | 5 mg | $44.99 | — | 66 |
| Crystal Peptides | 10 mg | $79.99 | — | 66 |
| Nox Amino | 10 mg | $95.00 | — | 55 |
| Peptiatlas | 20 mg | — | — | 51 |
| Peptiatlas | — | — | — | 51 |
| Taishijie | — | — | — | 51 |
| Taikangbio | — | — | — | 50 |
| Zjpeptix | — | — | — | 50 |
| Hkuppeptide | 20 mg | $10.00 | — | 50 |
| Hkuppeptide | 10 mg | $10.00 | — | 50 |
| Hkuppeptide | 15 mg | $10.00 | — | 50 |
| Hkuppeptide | 20 mg | $10.00 | — | 50 |
| Hkuppeptide | 10 mg | $10.00 | — | 50 |
| MEI-PEPETIDE | 2 mg | $45.00 | — | 48 |
| DongCheng Peptide | — | — | — | 46 |
| Mandy | 5 mg | $26.00 | — | 43 |
| HongDa Peptide | — | $40.00 | — | 43 |
| zztai Peptide Ltd | — | — | — | 43 |
| MJT peptides | 5 mg | $37.00 | — | 39 |
| HK Peptide Ltd (hk peptides) | 10 mg | $60.00 | — | 37 |
| Apollo Peptide Sciences | 5 mg | $79.99 | — | — |
| Apollo Peptide Sciences | 10 mg | — | — | — |
| Apollo Peptide Sciences | 15 mg | $159.99 | — | — |
| Bulk Peptides | 10 mg | $200.00 | — | — |
| Polaris Peptides | 20 mg | $175.00 | — | — |
| Polaris Peptides | 12.5 mg | $105.00 | — | — |
| Polaris Peptides | 5 mg | $50.00 | — | — |
| Polaris Peptides | 2 mg | $30.00 | — | — |
| Polaris Peptides | 10 mg | $90.00 | — | — |
Research
Background This phase 2 study evaluated once-weekly zalfermin and semaglutide for efficacy and safety in patients with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, including patients with compensated cirrhosis (F4c).
source →Background Semaglutide, a glucagon-like peptide-1 receptor agonist, effectively promotes weight loss and improves metabolic parameters in individuals with obesity. However, its use is often accompanied by reductions in lean mass, raising concerns about long-term muscle health.
source →Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.
source →Aims Neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin-based therapies for type 2 diabetes mellitus (T2DM) and obesity. However, whether risks differ across successive generations of incretin-based therapies remains uncertain.
source →This retrospective cohort study evaluated whether semaglutide and tirzepatide reduce the risk of falls and femoral fractures in older adults with type 2 diabetes and overweight or obesity. The findings showed significantly lower risks of both outcomes compared with DPP-4 inhibitors.
source →Aim In December 2022, semaglutide injections for weight management were marketed in Denmark. Pre-marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed.
source →Latent autoimmune diabetes in youth (LADY) is a poorly characterized form of autoimmune diabetes with onset between 8 and 29 years of age and with slow progression toward insulin dependence, similarly to latent autoimmune diabetes of the adult (LADA), which leads to diagnostic difficulties and possibly to therapeutic i…
source →Purpose To report a case of bilateral non-arteritic optic neuropathy (NA-AION) associated with unilateral branch retinal artery occlusion (BRAO) following semaglutide exposure and the partial improvement of bilateral disc swelling and partial recovery of visual function after the discontinuation of Semaglutide.
source →Background and hypothesis Semaglutide is a glucagon-like peptide-1 receptor agonist widely used for its glucose-lowering effects in people with type 2 diabetes (T2D), as well as its cardiovascular and kidney-protective properties.
source →Semaglutide is often optimized to maximize weight loss, yet it remains unclear whether long-term cardiovascular benefit is more closely associated with achieved weight reduction or therapeutic exposure. We conducted a retrospective observational study using a federated, de-identified U.S.
source →Importance Consistent results from preclinical and clinical studies indicate that activation of glucagon-like peptide-1 receptors (GLP-1 Rs) affects reward processes; however, to our knowledge, no study has previously evaluated whether a GLP-1 R agonist (GLP-1 RA) affects motivated behavior in individuals with major de…
source →Background This scoping review aims to explore existing clinical trials on the association between semaglutide use and the occurrence of retinal vascular events to detect any potential safety concern.
source →The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength.
source →The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.
source →The aim of this clinical trial is to investigate whether oral semaglutide can be used to treat open-angle glaucoma.
source →Background: Post-transplant hyperglycaemia occurs frequently in renal transplant recipients within the first two weeks after transplantation. Standard-of-care is primarily based on insulin treatment with the adherent risk of hypoglycaemia and weight gain.
source →Systematic review and meta-analysis of semaglutide for weight loss in obesity without diabetes; consistent, clinically meaningful reductions.
source →Phase 3 RCT (STEP 1): once-weekly semaglutide 2.4 mg produced ~15% mean body-weight reduction vs placebo over 68 weeks in adults with overweight or obesity.
source →RCT (STEP 4): continued semaglutide 2.4 mg maintained weight loss; switching to placebo led to regain, supporting ongoing treatment.
source →This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine. In addition, the study will also look at the effect of semaglutide on the participant's appetite and energy intake.
source →This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a meal. The study will last up to 40 weeks, including a 28-week treatment period.
source →Type II diabetes is a known risk factor for heart failure, particularly through the progressive development of diabetic cardiomyopathy. Cardiac metabolic parameters, including myocardial steatosis and epicardial fat, are altered in diabetic patients.
source →This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
source →